Febe van Maldegem

Lung adenocarcinoma promotion by air pollutants

William Hill, Emilia L. Lim, Clare E. Weeden et al. · Nature · 2023 · 761 citations · Full text

Medicine, Oncology, Toxicology +14

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Míriam Molina‐Arcas, Christopher Moore, Sareena Rana et al. · Science Translational Medicine · 2019 · 220 citations

Medicine, Oncology, Pharmacology +16

Differential expression of interleukin‐17 family cytokines in intact and complicated human atherosclerotic plaques

Onno J. de Boer, J. J. van der Meer, Peter Teeling et al. · The Journal of Pathology · 2009 · 184 citations

Life Sciences, Cardiology, Immunology +17

Therapeutic KRAS ^G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers

Edurne Mugarza, Febe van Maldegem, Jesse Boumelha et al. · Science Advances · 2022 · 137 citations · Full text

Life Sciences, Immunology, Oncology +17

The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment

Febe van Maldegem, Remco van Dijk, Thera A.M. Wormhoudt et al. · Blood · 2008 · 110 citations · Full text

Medicine, Dermatology, Immunology +11